
Regulatory
Latest Content

Gilead Signs Royalty-Free Licensing Deals to Broaden Access to Obeldesivir

FDA Approves Cosentyx for Polymyalgia Rheumatica, Wilserdly for ER-Positive ESR1-Mutated Advanced Breast Cancer

How Pharma Workflows Are Impacted by Agentic Models Beyond Productivity Gains

Pharmaceutical Executive Daily: FDA Approves Three New Therapies

M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD Therpaeutics Acquires AD04 Alzheimers Program, Sanofi Enters Collaboration with Seawolf Therapeutics

Shorts









Podcasts
Videos
All News

FDA approves Genentech’s Gazyva, Alexion’s Klygefa, and Teva’s Igalm.

Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.

Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.

Pharma field forces face three key challenges: scaling services beyond tier one, shifting from reactive to proactive engagement, and empowering teams with agentic AI.

FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.

FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.

Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.

Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.

Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.

With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.

FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

FDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.





















